{"id":"W2561439167","doi":"10.1093/annonc/mdw665","title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":104,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital du Saint-Sacrement; University of Toronto; Sunnybrook Health Science Centre; Canadian Red Cross Society","funders":"Eisai; Genentech; AstraZeneca; Chugai Pharmaceutical; Amgen; Pfizer; F. Hoffmann-La Roche","keywords":"Medicine; Bevacizumab; Adjuvant; Adjuvant therapy; Triple-negative breast cancer; Breast cancer; Oncology; Randomized controlled trial; Internal medicine; Surgery; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008145874,0.001042237,0.002384133,0.0004792577,0.0005532709,0.001926201,0.0009757227,0.001537865,0.005682258],"category_scores_gemma":[0.01016574,0.0005001096,0.002778299,0.0005823639,0.0005904796,0.001302071,0.0005742277,0.002914798,0.0009954964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001091496,"about_ca_system_score_gemma":0.00129366,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001585413,"about_ca_topic_score_gemma":0.005173863,"domain_scores_codex":[0.9971651,0.001726421,0.0001563663,0.0002991699,0.0004025122,0.0002504968],"domain_scores_gemma":[0.9937309,0.002582666,0.00149104,0.0007456898,0.000733724,0.0007159257],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8315637,0.002853314,0.009533037,0.001756811,0.01511712,0.0001525825,0.0001493884,0.001894145,0.005982306,0.0007895416,0.02474318,0.1054649],"study_design_scores_gemma":[0.7857661,0.05872557,0.08369984,0.0004825783,0.02894536,0.0005000092,0.0001422619,0.001460564,0.003517363,0.002562969,0.03405664,0.0001408167],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8666982,0.04350492,0.004489494,0.009291462,0.001913474,0.003784291,0.03738962,0.0005095612,0.03241893],"genre_scores_gemma":[0.9345381,0.007302179,0.004312505,0.007149764,0.001261236,0.002001691,0.03204117,0.0001854162,0.01120799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008145874,"threshold_uncertainty_score":0.04307997,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06968499473878104,"score_gpt":0.4052475702943823,"score_spread":0.3355625755556013,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}